IN8bio (Nasdaq:INAB) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

INAB Stoklara Genel Bakış

INAB temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Hissedarlar geçen yıl sulandırıldı

Anlamlı bir piyasa değeri yok ( $13M )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

+ 1 daha fazla risk

IN8bio, Inc. Rakipler

Inhibitor Therapeutics

OTCPK:INTI

US$15.5m

Indaptus Therapeutics

NasdaqCM:INDP

US$12.0m

Edesa Biotech

NasdaqCM:EDSA

US$15.2m

Sensei Biotherapeutics

NasdaqGM:SNSE

US$12.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti IN8bio
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.26
52 Haftanın En Yüksek Seviyesi	US$2.48
52 Haftanın En Düşük Seviyesi	US$0.24
Beta	-0.051
11 Aylık Değişim	-47.21%
3 Aylık Değişim	-67.00%
1 Yıllık Değişim	-73.06%
33 Yıllık Değişim	-95.84%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-97.36%

Son Haberler & Güncellemeler

IN8bio (NASDAQ:INAB) Will Have To Spend Its Cash Wisely

Aug 06

Recent updates

Hissedar Getirileri

	INAB	US Biotechs	US Pazar
7D	-7.4%	-0.2%	-0.4%
1Y	-73.1%	22.1%	34.1%

Getiri vs. Endüstri: INAB geçen yıl % 22.1 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: INAB geçen yıl % 34.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is INAB's price volatile compared to industry and market?
INAB volatility
INAB Average Weekly Movement	13.0%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: INAB hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: INAB 'nin haftalık oynaklığı ( 13% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2016	39	William Ho	in8bio.com

Klinik aşamada bir biyofarmasötik şirketi olan IN8bio, Inc. katı ve sıvı tümörlerin tedavisi için gama-delta T hücre tedavilerinin keşfi, geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Şirketin öncü ürün adayları arasında yeni teşhis edilmiş glioblastoma (GBM) tedavisi için Faz 2 klinik çalışmasında olan INB-400; GBM ve diğer kanserlerin tedavisi için Faz I klinik çalışmasında olan genetik olarak modifiye edilmiş otolog gama-delta T hücre ürün adayı INB-200; ve hematopoetik kök hücre nakli yapılan hematolojik maligniteli hastaları tedavi etmek için Faz I klinik çalışmasında olan allojenik ürün adayı INB-100 bulunmaktadır. Şirket, akut miyeloid lösemi ve diğer solid ve hematolojik tümör tiplerinin tedavisi için klinik öncesi aşamada olan INB-300 ve INB-500'ü geliştirmektedir.

IN8bio, Inc. Temel Bilgiler Özeti

IN8bio'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
INAB temel i̇stati̇sti̇kler
Piyasa değeri	US$12.33m
Kazançlar(TTM)	-US$31.96m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.4x

F/K Oranı

INAB aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
INAB gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$31.96m
Kazançlar	-US$31.96m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.68
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

INAB uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

INAB Stoklara Genel Bakış

Ödüller

Risk Analizi

IN8bio, Inc. Rakipler

OTCPK:INTI

US$15.5m

NasdaqCM:INDP

US$12.0m

NasdaqCM:EDSA

US$15.2m

NasdaqGM:SNSE

US$12.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

IN8bio, Inc. announced that it expects to receive $12.405547 million in funding

IN8bio, Inc. Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio, Inc. Announces Updated Positive Clinical Data from Both of the Phase 1 Investigator-Sponsored Trials of INB-100 for Hematological Malignancies and INB-200 for GBM

IN8bio (NASDAQ:INAB) Will Have To Spend Its Cash Wisely

IN8bio, Inc. Presents Positive Data Demonstrating Durable 1-Year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

IN8bio, Inc. Presents Progression-Free Survival Update from Phase 1 Study of INB-200 At 2024 American Society of Clinical Oncology Annual Meeting

Recent updates

IN8bio, Inc. announced that it expects to receive $12.405547 million in funding

IN8bio, Inc. Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio, Inc. Announces Updated Positive Clinical Data from Both of the Phase 1 Investigator-Sponsored Trials of INB-100 for Hematological Malignancies and INB-200 for GBM

IN8bio (NASDAQ:INAB) Will Have To Spend Its Cash Wisely

IN8bio, Inc. Presents Positive Data Demonstrating Durable 1-Year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

IN8bio, Inc. Presents Progression-Free Survival Update from Phase 1 Study of INB-200 At 2024 American Society of Clinical Oncology Annual Meeting

In8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation At Asgct 2024

In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma

IN8bio, Inc., Annual General Meeting, Jun 12, 2024

IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

We're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Rate

New major risk - Financial position

IN8bio, Inc. to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

IN8bio, Inc. announced that it has received $14.442298 million in funding from Bios Equity Partners LP

New major risk - Shareholder dilution

Price target decreased by 16% to US$11.00

IN8bio, Inc. Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

IN8bio, Inc. Appoints Corinne Epperly to the Board of Directors

IN8bio, Inc.’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

IN8bio, Inc. Presents Biologic Correlative Data from the Inb-200 Phase 1 Trial in Newly Diagnosed Glioblastoma At the Society for Immunotherapy of Cancer's 38Th Annual Meeting

IN8bio, Inc. Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Companies Like IN8bio (NASDAQ:INAB) Could Be Quite Risky

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

IN8bio, Inc. Announces Presentations at the Society for Immunology of Cancer 38th Annual Meeting

IN8bio, Inc. Announces Updated Data from the Ongoing Phase 1 Clinical Trial of Inb-200 in Patients with Newly Diagnosed Glioblastoma Multiforme

IN8bio, Inc. Announces Positive Preclinical Data Underscoring the Potential of Its DeltEx Gamma-Delta T Cells to Target and Kill Ovarian Cancer

Is IN8bio (NASDAQ:INAB) In A Good Position To Invest In Growth?

IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

In8bio Announces New Data At Ash Showing 100% of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of Inb-100

IN8bio Announces FDA Clearance to Initiate A Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma

Price target decreased to US$9.67

High number of new and inexperienced directors

IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting

High number of new and inexperienced directors

Here's Why We're Watching IN8bio's (NASDAQ:INAB) Cash Burn Situation

High number of new and inexperienced directors

IN8bio, Inc. Appoints Michael R. Bishop to Its Scientific Advisory Board

IN8bio gains 53% as H.C. Wainwright initiates with Buy

Independent Director recently bought US$200k worth of stock

IN8bio raises additional funds from underwriter of stock offering

IN8bio prices $10.25M stock offering

IN8bio, Inc. Provides Clinical Update from Ongoing Phase 1 Trial of INB-100

IN8bio, Inc. Appoints Kenneth R. Lamontagne as Senior Vice President, Business Development

IN8bio, Inc. Announces Positive Glioblastoma Multiforme (Gbm) Clinical Updates from the INB-200 Phase 1 Trial Presented At Asco 2022

We're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Rate

IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform

IN8bio, Inc., Annual General Meeting, Jun 01, 2022

IN8bio, Inc. Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100

IN8bio (NASDAQ:INAB) Is In A Good Position To Deliver On Growth Plans

IN8bio, Inc. Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme

In8bio Provides Update from the Ongoing Phase 1 Clinical Trial of Its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

IN8bio, Inc. Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

Director recently bought US$1.0m worth of stock

IPO Update: IN8bio Aims For Downsized IPO

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

IN8bio, Inc. Temel Bilgiler Özeti